JPS588018A - Cathartic - Google Patents

Cathartic

Info

Publication number
JPS588018A
JPS588018A JP56106684A JP10668481A JPS588018A JP S588018 A JPS588018 A JP S588018A JP 56106684 A JP56106684 A JP 56106684A JP 10668481 A JP10668481 A JP 10668481A JP S588018 A JPS588018 A JP S588018A
Authority
JP
Japan
Prior art keywords
lactobacillus
lactose
spores
fermentation
cathartic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP56106684A
Other languages
Japanese (ja)
Other versions
JPS6355493B2 (en
Inventor
Akira Yamauchi
昌 山内
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP56106684A priority Critical patent/JPS588018A/en
Publication of JPS588018A publication Critical patent/JPS588018A/en
Publication of JPS6355493B2 publication Critical patent/JPS6355493B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

PURPOSE:A cathartic that is prepared by allowing a microorganism of Lactobacillus such as Lactobacillus bifidus to act on lactose, thus permitting effective application for a long period of time without bellyache and habituation. CONSTITUTION:The substrate after fermentation of Lactobacillus bifidus, Lactobacillus natto, yeast or other microorganisms is directly dried to prepare a half-dried product or dried powder containing all of living cells, spores and enzymes and the product is used as the base substance. Or at least one selected from living cells of Lactobacillus other than L. natto and yeasts, spores and culture mixture is made to act on lactose to produce the objective cathartic. The coexistence of the above fermentation seed with lactose and water permits the proliferation of Lactobacillus cells in the seed and the carbon dioxide evolving during the fermentation is utilized to develop the cathartic action. The amount of lactose is desired to be as much as possible to the fermentation seed.

Description

【発明の詳細な説明】 本発明は、主として乳酸菌類と乳糖を用いて作成した下
剤に関する。一般に下剤は、腸壁に接するか、腸壁より
吸収されて、神経を刺滅すること順次増量の必要が生じ
たり、 長期の服用によっては、腸の神経が麻痺して、重度の便
泌症となるといった副作用があり九。又、近来、肉食が
普及し、植物性繊維の不足のため慢性便泌の患者が増え
、腸に内臓する宿便が種々の疾病、癌でさえもの原因と
目されるに至り、このため、長期服用しても副作用の発
生しない下剤又は排便促進剤が求められていた。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a laxative mainly made using lactic acid bacteria and lactose. In general, laxatives come into contact with the intestinal wall or are absorbed through the intestinal wall, irradiating the nerves, making it necessary to gradually increase the dose, or, depending on long-term use, paralyzing the intestinal nerves and causing severe fecal discharge. There are 9 side effects such as: In addition, in recent years, as meat eating has become popular, the number of patients with chronic fecal secretion has increased due to lack of vegetable fiber, and fecal impaction in the intestines has come to be seen as the cause of various diseases and even cancer. There has been a need for a laxative or a defecation stimulant that does not cause side effects when taken.

末完明けこれらの必要を完全にみたさんとするもので、
これを順次説明すると、 一般に、乳酸菌は乳糖を、納豆菌Fi蛋白質を、酵母は
多糖類を分解することによって増殖し、この際多量のC
O,ガスを副生せしめるが、本発明は人体に無害なとの
CO,ガスの持つ物理的圧力とco。
At the end of the day, these needs will be completely fulfilled.
To explain this sequentially, in general, lactic acid bacteria proliferate by decomposing lactose, Bacillus natto Fi protein, and yeast proliferates by decomposing polysaccharides.
O, gas is produced as a by-product, but the present invention uses CO, which is harmless to the human body, and the physical pressure that the gas has.

ガス発生期の刺激作用を活用して下剤にしようとするも
のである。現在、医薬品や食品として利用される酵素末
と称されるものは、各種の微生物を培饗して酵素を生産
せしめた培養基からアルコール、アセトン等の溶剤を用
いて酵素のみを純粋な形で抽出するものであるが、本発
明では、少なくともグイフイルズ菌等の乳酸菌類き乳糖
よりなることを構成すべく、まず乳酸菌を調整するもの
で、例えばグイフィルズ菌等の乳酸菌類、納豆菌類、酵
母類等の醗酵後の培養基(この場合少なくとも乳酸菌類
が含まれることが条件となる)をそのまま乾燥して、生
菌、芽胞、WI素のすべてを含む半乾燥物又は乾燥粉末
を作り、これを基本物質(以下これを醗酵素と称す)と
して用いたり、又は納豆菌類や酵母類を含まない乳酸菌
類の生菌、芽胞。
It is intended to be used as a laxative by utilizing its stimulatory effect during the gas generation period. Currently, what is called enzyme powder used in medicines and foods is made by extracting enzymes in pure form using solvents such as alcohol and acetone from a culture medium in which various microorganisms have been cultivated to produce enzymes. However, in the present invention, the lactic acid bacteria are first prepared in order to form a composition consisting of at least lactic acid bacteria such as Guiphyllus bacteria, and lactose. After fermentation, the culture medium (in this case, it must contain at least lactic acid bacteria) is dried as it is to create a semi-dry product or dry powder containing all viable bacteria, spores, and WI elements, and this is used as a basic substance ( (hereinafter referred to as enzyme), or live bacteria and spores of lactic acid bacteria that do not contain natto fungi or yeast.

培養基の一種又は二種以上(以下これをも醗酵素と称す
)を選択するものである。ここに醗酵素は、組成的には
、生菌、芽胞、酵素、培養基に分けることができるが、
生菌は商品として流通中に采死状11になり、芽胞、酵
素は乾燥状態に耐えることが出来るもので、胃袋力・ら
小jIK入ってw4#素が溶解されるにつれ、先づ酵素
が直ちに作用を開始し、続いて生菌がよみがえり、やが
て芽胞が微水して芽生え、増殖し始めることになる。培
養基は商品流通中には、外気との保護作用を行い服用後
は細菌類のなじみのある栄II素としても働くものと考
えられる。
One or more types of culture media (hereinafter also referred to as enzymes) are selected. In terms of composition, enzymes can be divided into live bacteria, spores, enzymes, and culture media.
Live bacteria become dead during distribution as a product, and spores and enzymes can withstand dry conditions. The action begins immediately, and then the viable bacteria are revived, and eventually spores start to grow and multiply. It is thought that the culture medium acts as a protective agent against the outside air during product distribution, and after taking the product, it also acts as a nutrient II that is familiar to bacteria.

本発明は、上記の様な順序で作用するのであるから、速
効のある酵素は多い程よいが、これは定量的に働くので
、下痢作用をもたらす程度に服用することけ先づ困難で
あり、生菌、芽胞が大半の働きをするものと考えられる
。ちなみに微生物、例えば乳酸lll1グは、1夜で約
1億ケに増えるものではあるが、胃液中を通過して腸内
に到着して増殖しはじめるまでに相当な消耗を考えねば
ならず、効果の信頼性のために醗酵素1!中く生菌。
In the present invention, since the enzyme acts in the order described above, the more rapidly acting enzymes are used, the better; however, since the enzyme acts quantitatively, it is difficult to take the dose to the extent that it causes diarrhea, and It is thought that bacteria and spores do most of the work. By the way, microorganisms, such as lactic acid, can increase to about 100 million in one night, but they must be consumed considerably before they pass through the gastric fluid, reach the intestines, and begin to multiply. Enzyme 1 for reliability! Live bacteria inside.

芽胞を10’−10°ケを含有したものを使用すべきで
ある。
One containing 10'-10' of spores should be used.

本発明は、このような醗酵素を乳糖と水分に共存させる
ことで醗酵素中の乳酸菌の増殖を可能とし、このとき発
生するco、ガスの利用が下剤としての効果を発揮させ
るものである。
The present invention enables the growth of lactic acid bacteria in the lactose by allowing the lactose to coexist with water, and utilizes the cobalt and gas generated at this time to exert the effect as a laxative.

なお、1Iis素に対して使用する乳糖の量か少々けれ
ば下剤としての効果の発揮が困難であるから、その使用
量は、なるべく大量であることが望まれる。例えば、個
人差もあるが成人には歇+クリム   ゛以上の量を用
いるのが望壇れる。しかし、使用対象に応じその量は適
宜調整される。
It should be noted that if the amount of lactose used per 1Iis base is small, it will be difficult to exert the effect as a laxative, so it is desirable that the amount used be as large as possible. For example, although there are individual differences, it is recommended for adults to use an amount of more than 100ml + cream. However, the amount is adjusted as appropriate depending on the intended use.

本発明は一例として次の処方で実施される。The present invention is implemented with the following formulation as an example.

処方(1)   醗酵素          IP粉ミ
ルク(又は豆乳末) 8o2 乳糖    30P 温湯又は冷水     200y これらを混合したものを空腹時に1回分さして服用する
と、普通1時間前後から腹鳴かあり、腹張りの自覚が進
み、やがて便意をもよおして、通常2〜3時間前後して
かなりのガスと共に大量の排便を見ることKなり、これ
が時間をおいて2〜3回繰り返され、腸内の便が殆んど
一掃されるが、完全に終了した後は極めて爽快な感覚が
残る。これは、通常1日1回朝食代りに服用するが、人
によって個人差があり、2〜3日かかってこのような結
果を見る人もあり、排便後は通常の下剤のように残留感
が全くなく又、この服用を止めると直ちに平常のベース
に復帰して通常便を見ることが出来る。この方法は、ガ
スが出るということ以外は腹痛もなく、習慣性もなく、
常用しても大腸性の下痢のために栄餐障害もない。又、
味も美味で、朝食代りとして常用することで、宿便のた
めに生じるといわれるふき出もの、じんましん、ぜんそ
く等のアレルギーけじめ高血圧、不眠、肩こり、太りす
ぎ迄にも著効を見ることが出来る。
Prescription (1) Enzyme IP powdered milk (or soybean milk powder) 8o2 Lactose 30P Hot or cold water 200Y If you take a mixture of these in one dose on an empty stomach, you will usually experience borborygmi after about an hour, and your awareness of abdominal bloating will increase. Eventually, the person will have the urge to defecate, and usually after about 2 to 3 hours will have a large amount of defecation with considerable gas, and this will be repeated 2 to 3 times at intervals, until most of the feces in the intestines are cleared out. However, once it's completely finished, you'll be left with an extremely exhilarating feeling. This is usually taken once a day in place of breakfast, but it varies from person to person, and some people may take 2 to 3 days to see these results, and after defecating, there is a residual feeling like a normal laxative. Not at all, and as soon as I stop taking this medication, my condition returns to normal and I can have normal stools. This method causes no abdominal pain other than gas, and is not addictive.
Even with regular use, there is no problem with eating habits due to large intestine diarrhea. or,
It has a delicious taste, and by regularly using it as a breakfast substitute, it can be effective against allergies such as pimples, hives, and asthma, which are said to be caused by fecal impaction, as well as high blood pressure, insomnia, stiff shoulders, and even being overweight.

なお、本発明は無酵素の状態でも生育する人体有益菌を
使用するので、上記の有害菌の生育をおさえ、腸内の状
態を細菌的に清浄にするのみでなく、この際、有益菌が
生産する各種の#ll#′i腸の内HIKある宿便を分
解排出する効果もあ抄、又処方(りの例にみるミルク配
合を除けば、乳糖は上記のように分解されCO,ガス発
生と同時に分解吸収されるが、乳成分中の蛋白質も納豆
菌によって分解、吸収され、栄餐的にも長期の使用に不
安はないO 以上処方(1)は各成分の混合物を作成と同時に服用し
たが、服用前2〜3時間又は数時間以上コツプ等に入れ
て放置しておくことにより、乳酸菌、乳糖の溶液中では
醗酵が始まり、これを服用することで下剤としての機能
け、服用彼達やかに発揮され、未発明の目的を即座に遠
戚できる。
Furthermore, since the present invention uses bacteria that are beneficial to the human body and can grow even in the absence of enzymes, it not only suppresses the growth of the above-mentioned harmful bacteria and cleanses the intestine from a bacterial perspective, but also allows beneficial bacteria to grow in the absence of enzymes. It also has the effect of decomposing and excreting the fecal impaction that is high in the intestines produced by various types of #ll#'i. At the same time, it is decomposed and absorbed, but the protein in the milk component is also decomposed and absorbed by Bacillus natto, so there is no need to worry about long-term use nutritionally.For prescription (1) above, take the mixture at the same time as making the mixture of each component. However, if you leave it in a pot for 2-3 hours or more than a few hours before taking it, fermentation will begin in the solution of lactic acid bacteria and lactose, and when you take it, it will function as a laxative. It is swiftly exerted, and an uninvented purpose can be instantly related to a distant relative.

処方(2)   醗酵素          12乳糖
    80り 黒糖    1ot 天然粉末ジュース     5f 各種ビタミン類     適 量 温湯又は冷水     250り 処方(2)は、ミルクにアレルギーのある人や栄養過多
の人のためのもので、これの混合物を一回量として服用
すると処方(1)と同様、1時間前後で腹張りの自覚が
進み、2〜3時間で大量の排便をみる。
Prescription (2) Enzyme 12 Lactose 80% Brown sugar 1t Natural powdered juice 5f Various vitamins Appropriate amount Hot or cold water 250% Prescription (2) is for people who are allergic to milk or overnourished. When the mixture is taken as a single dose, similar to prescription (1), the patient becomes aware of abdominal distension after about an hour and begins to defecate in large quantities within 2 to 3 hours.

上記のものを更に強力に作用せしめんとする場合は、こ
れに粉末コンニャダ(マンナンIn末)IPを加えて服
用すると、糖分の吸収をさまたげ、便通を促進し、太り
過ぎの治療、矢肌作りのために極めて有効である。
If you want to make the above effects even stronger, add powdered Konyada (mannan In powder) IP to it and take it.It will block sugar absorption, promote bowel movement, treat overweight, and improve the appearance of skin. It is extremely effective for this purpose.

未発明は以上のように極めて安全、安価な方法であり、
健康保持又は病気治療のために長期使用出来る効果的な
下剤であって、長期にわたり、食物の腐敗物が残留粘着
したと考えられる宿便け、腸壁表面に固着しており、人
員等の強い下剤で長期にわたって浣腸しても完全に取る
ことが困難であったが、本発明による浣腸では、水様の
ミルク便がガス圧よって拡張されたlI費を急速に通過
して洗い流すため、4日〜7日程度の治療でll11が
極めて清浄になっているのが内視鏡で観察することが出
来るうえに、この宿便の排出は、排便が黒く粘性があり
異臭のあることによってもa1訴することが出来る。
As mentioned above, the uninvented method is extremely safe and inexpensive.
It is an effective laxative that can be used for a long period of time to maintain health or treat diseases.It is a strong laxative for personnel, etc. that has been used for a long period of time to cause fecal impaction, which is thought to be due to the residual adhesion of decayed food, and which has adhered to the surface of the intestinal wall. However, with the enema of the present invention, the watery milky stool rapidly passes through the expanded lI due to gas pressure and is flushed away, so it can be removed completely even if the enema is administered for a long period of time. After about 7 days of treatment, it can be observed with an endoscope that the ll11 becomes extremely clean, and the excretion of this fecal impaction is also a complaint because the feces are black, viscous, and have a foul odor. I can do it.

ナオ、本発明は粉末を主として説明したが、これを乳糖
その他を液剤にして醗酵素を別封し、これを同時に服用
するとか、処方通りの成分を角砂糖又は錠剤、あめ状に
加工し服用に便宜を与えるのけ自由である。
Nao, the present invention has mainly been explained as a powder, but it can be made into a liquid with lactose or other ingredients, packaged with enzyme separately, and taken at the same time, or processed into sugar cubes, tablets, or candy-like ingredients as prescribed and taken. He is free to give conveniences.

特許出願人  山 内   昌Patent applicant Masaru Yamauchi

Claims (4)

【特許請求の範囲】[Claims] (1)ゲイフイルズ菌等の乳酸菌類を乳糖に作用させて
なる下剤
(1) A laxative made by letting lactic acid bacteria such as Lactobacillus gayphilus act on lactose.
(2)乳酸菌類を生菌の状態で用いてなる特許請求の範
囲第1項記載の下剤□−
(2) A laxative according to claim 1, which uses lactic acid bacteria in the form of living bacteria □-
(3)乳酸菌類を゛芽胞の状態で用いてなる特許請求の
*@U!1項記載の下剤
(3) The patent claim *@U! which uses lactic acid bacteria in the form of spores! Laxatives listed in item 1
(4)乳酸菌類を#素を含んだ培査基の状態で用いてな
る特許請求の範囲第1項記載の下剤(5)乳酸−類を生
1、芽胞、培養基から選んだ二以上を組合せてなる特許
請求の範囲第1〜4項記載の下剤
(4) A laxative according to claim 1, which uses lactic acid bacteria in the form of a culture medium containing # element. (5) A combination of two or more lactic acids selected from raw 1, spores, and culture medium. A laxative according to claims 1 to 4 consisting of
JP56106684A 1981-07-07 1981-07-07 Cathartic Granted JPS588018A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP56106684A JPS588018A (en) 1981-07-07 1981-07-07 Cathartic

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56106684A JPS588018A (en) 1981-07-07 1981-07-07 Cathartic

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP60011553A Division JPS60214740A (en) 1985-01-23 1985-01-23 Purgative

Publications (2)

Publication Number Publication Date
JPS588018A true JPS588018A (en) 1983-01-18
JPS6355493B2 JPS6355493B2 (en) 1988-11-02

Family

ID=14439885

Family Applications (1)

Application Number Title Priority Date Filing Date
JP56106684A Granted JPS588018A (en) 1981-07-07 1981-07-07 Cathartic

Country Status (1)

Country Link
JP (1) JPS588018A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60214740A (en) * 1985-01-23 1985-10-28 Akira Yamauchi Purgative
JPS6163618A (en) * 1984-09-03 1986-04-01 Akira Yamauchi Cathartic
US5656268A (en) * 1995-04-21 1997-08-12 Sorodsky; Michael Biological product
EP1506781A1 (en) * 2003-11-03 2005-02-16 Peter-Hansen Volkmann Vaginal care composition

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6163618A (en) * 1984-09-03 1986-04-01 Akira Yamauchi Cathartic
JPH0368010B2 (en) * 1984-09-03 1991-10-25 Akira Yamauchi
JPS60214740A (en) * 1985-01-23 1985-10-28 Akira Yamauchi Purgative
US5656268A (en) * 1995-04-21 1997-08-12 Sorodsky; Michael Biological product
EP1506781A1 (en) * 2003-11-03 2005-02-16 Peter-Hansen Volkmann Vaginal care composition

Also Published As

Publication number Publication date
JPS6355493B2 (en) 1988-11-02

Similar Documents

Publication Publication Date Title
CN109730308A (en) Tranquilizing the mind nourishing heart enhances memory effect Sialic acid complex polypeptide nutrition element and preparation method
JPS588018A (en) Cathartic
Kellogg Autointoxication; Or, Intestinal Toxemia
CN109700031A (en) For cleaning intestinal tract, the alimentation composition of enteron aisle toxin expelling
Harris Health on the Farm
CN114343180A (en) A series of compositions with effects of clearing hollow viscera and removing toxic substance, and its application
Haggard The science of health and disease: a textbook of physiology and hygiene
TW202114542A (en) Prebiotic composition for promoting growth ofclostridium butyricumand uses thereof
CN104116999A (en) Preparation for improving intestinal microbial environment and preparation method thereof
JPS60214740A (en) Purgative
Kellogg The New Dietetics, What to Eat and How
Walker Vegetarian Guide to Diet and Salad
Meyerowitz Juice Fasting and Detoxification: Use the Healing Power of Fresh Juice to Feel Young and Look Great
Money Treatment of Disease in Children: Including the Outlines of Diagnosis and the Chief Pathological Differences Between Children and Adults
Kellogg Colon Hygiene, Comprising New and Important Facts Concerning the Physiology of the Colon and an Account of Practical and Successful Methods of Combating Intestinal Inactivity and Toxemia
Kellogg The Stomach
Kilmer The story of the papaw
Davis Food in health and disease
Kellogg The Home Book of Modern Medicine: A Family Guide in Health and Disease
KR101451952B1 (en) Composition and food for treating hangover containing hiliscus syriacus
Richter et al. Nature, the Healer
Haggard What You Should Know About Health and Disease
Thompson A Text-book of Practical Medicine
Christopher Summer complaint and infant feeding
Saundby The Treatment of Diseases of the Digestive System